Catalent Presents At 38th Annual CRS Conference

Catalent Expert Presents New Technologies, Advancing Controlled Release and ODT Tablet Design Options at 38th Annual CRS Conference

Somerset, NJ –July 28, 2011 — Michael J. Valazza R.Ph., Vice President, Global Modified Release Technologies, Catalent Pharma Solutions, will be presenting at the 38th Annual Controlled Release Society Conference on July 30-August 3, 2011, at National Harbor, Maryland.  Mr. Valazza’s presentation, “Recent Advances in Oral Disintegrating Tablets, Oral Granules and Bi-Layer Tablets Technologies”, will take place on Sunday, July 31 from 8:30 – 9:30 AM as part of a releasing technology workshop (Maryland rooms 3 and 4). This workshop will focus on new advancements in modified controlled release technologies, including novel OSDrC® OPTIDOSE™ optimized dose delivery technology, controlled release and Lyopan® orally fast-dissolve technologies.

Optimized Products and Better Treatments:

OSDrC® OPTIDOSETM optimized dose delivery technology offers the broadest range of controlled release, combination (tablet-within-a-tablet) products, and orally disintegrating tablets to optimize dosing, therapeutic, and plasma release profiles to meet patient needs in a high quality, one step manufacturing process.

To find out more about Catalent’s OSDrC® OPTIDOSETM optimized dose delivery technology, please visit:

Lyopan® technology offers the potential for increasing the range of prescription and consumer drug products that can be formulated as a lyophilized fast- dissolve dosage form because it uses less water. This proprietary technology may be applicable to the formulation of higher doses of soluble drugs than is currently feasible and may enable incorporation of coated API for enhanced taste-masking and controlled release.

To find out more about Catalent’s Lyopan® fast-dissolve lyophilized tablet technology, please visit:

Throughout his 30 year career, Mr. Valazza has held various executive positions in product development and technical services with a focus on modified and controlled release solid dosage form applications. He is a recognized leader in the field of controlled release technology, having published articles in several scientific journals, and presented at numerous industry conferences.  He currently leads Catalent’s Controlled Release Technologies global team, and is based at their Somerset, NJ headquarters.  Mr. Valazza is a registered pharmacist in New Jersey and Kentucky, with a Bachelor’s degree in Pharmacy from Rutgers University, College of Pharmacy.  He is a member of the Controlled Release Society (CRS) and American Association of Pharmaceutical Scientists (AAPS).

To arrange a follow-up interview with Mr. Valazza, please contact Patricia McGee at: .

For more information or to register for the conference, go to:

To learn more about Catalent’s Modified Release technologies, go to:

About Catalent

From drug and biologic development services to delivery technologies to supply solutions, Catalent Pharma Solutions has the deepest expertise, the broadest offerings and the most unique technologies in the industry. With over 75 years of experience, Catalent helps customers get more molecules to market faster, enhance product performance, and provide superior, reliable manufacturing and packaging solutions. Catalent employs approximately 8,000 people at 24 facilities worldwide and in fiscal year 2010 generated more than $1.7 billion in annual revenue. Catalent is headquartered in Somerset, NJ.

more products. better treatments. reliably supplied.™

OSDrC® is a registered trademark of Sanwa Kagaku Kenkyusho Co., Ltd
Lyopan® is a registered trademark of Pantec AG